Q8BQR4
Gene name |
Kansl2 (Nsl2) |
Protein name |
KAT8 regulatory NSL complex subunit 2 |
Names |
NSL complex protein NSL2, Non-specific lethal 2 homolog |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:69612 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q8BQR4
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q8BQR4-F1 | Predicted | AlphaFoldDB |
22 variants for Q8BQR4
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3389378496 | 12 | N>I | No | EVA | |
| rs3389378476 | 64 | V>I | No | EVA | |
| rs229245707 | 98 | A>T | No | EVA | |
| rs3389349320 | 104 | K>* | No | EVA | |
| rs3406591934 | 131 | T>S | No | EVA | |
| rs3406614930 | 152 | D>V | No | EVA | |
| rs3406591956 | 152 | D>Y | No | EVA | |
| rs3406591982 | 153 | Q>L | No | EVA | |
| rs3406549522 | 154 | E>D | No | EVA | |
| rs3406864952 | 154 | E>V | No | EVA | |
| rs13464056 | 292 | Q>L | No | EVA | |
| rs3389402363 | 303 | L>S | No | EVA | |
| rs3389392899 | 329 | D>V | No | EVA | |
| rs3389385301 | 369 | Q>R | No | EVA | |
| rs3389378461 | 377 | L>Q | No | EVA | |
| rs3389384893 | 399 | P>S | No | EVA | |
| rs3389381707 | 409 | D>V | No | EVA | |
| rs3389402393 | 415 | G>S | No | EVA | |
| rs264278121 | 431 | L>I | No | EVA | |
| rs3389389607 | 436 | H>R | No | EVA | |
| rs226001567 | 461 | R>Q | No | EVA | |
| rs3389384825 | 471 | R>G | No | EVA |
No associated diseases with Q8BQR4
2 regional properties for Q8BQR4
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Potential DNA-binding domain | 28 - 92 | IPR025927-1 |
| domain | Potential DNA-binding domain | 308 - 364 | IPR025927-2 |
6 GO annotations of cellular component
| Name | Definition |
|---|---|
| actin cytoskeleton | The part of the cytoskeleton (the internal framework of a cell) composed of actin and associated proteins. Includes actin cytoskeleton-associated complexes. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| histone acetyltransferase complex | A protein complex that possesses histone acetyltransferase activity. |
| NSL complex | A histone acetyltransferase complex that catalyzes the acetylation of a histone H4 lysine residues at several positions. In human, it contains the catalytic subunit MOF, NSL1/KIAA1267, NSL2/KANSL2, NSL3/KANSL3, MCRS1, PHF20, OGT1, WDR5 and HCF1. |
| nucleoplasm | That part of the nuclear content other than the chromosomes or the nucleolus. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
No GO annotations of molecular function
| Name | Definition |
|---|---|
| No GO annotations for molecular function |
7 GO annotations of biological process
| Name | Definition |
|---|---|
| chromatin organization | The assembly or remodeling of chromatin composed of DNA complexed with histones, other associated proteins, and sometimes RNA. |
| histone H4-K16 acetylation | The modification of histone H4 by the addition of an acetyl group to a lysine residue at position 16 of the histone. |
| histone H4-K5 acetylation | The modification of histone H4 by the addition of an acetyl group to a lysine residue at position 5 of the histone. |
| histone H4-K8 acetylation | The modification of histone H4 by the addition of an acetyl group to a lysine residue at position 8 of the histone. |
| positive regulation of DNA-templated transcription | Any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription. |
| positive regulation of histone H3-K4 methylation | Any process that activates or increases the frequency, rate or extent of the covalent addition of a methyl group to the lysine at position 4 of histone H3. |
| regulation of dosage compensation by inactivation of X chromosome | Any process that modulates the frequency, rate or extent of dosage compensation, by inactivation of X chromosome. |
1 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q9H9L4 | KANSL2 | KAT8 regulatory NSL complex subunit 2 | Homo sapiens (Human) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MNRIRIHVLP | TNRGRITPVP | RSQEPLSCSF | THRPCSQPRL | EGQEFCIKHI | LEDKNAPFKQ |
| 70 | 80 | 90 | 100 | 110 | 120 |
| CSYVSTKNGK | RCPSAAPKPE | KKDGVSFCAE | HARRNALALH | AQMKKSNPGP | MGETLLCQLS |
| 130 | 140 | 150 | 160 | 170 | 180 |
| SYAKTELGSQ | TPESSRSEAS | RILDEDSWSD | GDQEPITVDQ | TWRGDPDSEA | DSIDSDQEDP |
| 190 | 200 | 210 | 220 | 230 | 240 |
| LKHAGVYTAE | EVALIMREKL | IRLQSLYIDQ | FKRLQHLLKE | KKRRYLHNRK | VEHEALGSSL |
| 250 | 260 | 270 | 280 | 290 | 300 |
| LTGPEGLLAK | ERENLKRLKC | LRRYRQRYGV | EALLHRQLKE | RRMLATDGAA | QQAHTTRSSQ |
| 310 | 320 | 330 | 340 | 350 | 360 |
| RCLAFVDDVR | CSNQSLPMTR | HCLTHICQDT | NQVLFKCCQG | SEEVPCNKPV | PVSLSEDPCC |
| 370 | 380 | 390 | 400 | 410 | 420 |
| PLHFQLPPQM | YKPEQVLSVP | DDLEAGPMDL | YLSAAELQPT | ESLPLEFSDD | LDVVGDGMPC |
| 430 | 440 | 450 | 460 | 470 | 480 |
| PPSPLLFDPS | LTLEDHSVTE | SAGDAGQMQA | AGDGCRSQGA | RSVEKAAFPQ | RGLATANGKP |
| EPTSIS |